Akiram Therapeutics Advances Cancer Drug Candidate in Clinical Trials
Akiram Therapeutics has progressed its cancer drug candidate AKIR001 through multiple clinical trial phases and secured key manufacturing agreements and funding. The company is developing targeted radiotherapy for cancer.
Swedish company Akiram Therapeutics is advancing its development of targeted radiotherapy for cancer patients. The company's drug candidate, AKIR001, has moved through various stages of Phase 1 clinical trials, including patient enrollment and cohort completions.
In October 2024, the company announced that AKIR001 received clearance to commence Phase 1 clinical trials. By November 2024, Akiram Therapeutics reported that its research was selected for presentation in the "Top Rated Oral Presentations" category at the EANM Congress. Early in 2025, the first patient was enrolled in the clinical study. In April 2025, the company announced it had completed cohort 2a and received clearance to begin evaluating cohort 2b in the Phase 1 trial of AKIR001. In May 2025, the study progressed to cohort 3.
Additionally, the company has entered into strategically important agreements and secured funding. In October 2024, an agreement was signed with a leading university hospital for the manufacturing of AKIR001 for cancer therapy. Prior to this, the company also received significant funding, including SEK 68 million for the clinical development of a drug candidate aimed at treating rare thyroid cancers. In March 2025, Akiram Therapeutics initiated a Eurostars-funded collaboration to develop next-generation targeted alpha therapeutics.
The scientific foundation for AKIR001 is further supported by publications in respected scientific journals. For instance, the Journal of Nuclear Medicine published a study on AKIR001 in March 2026, reinforcing its scientific basis. The company has also been active in industry conferences and publications, showcasing its advancements in the field of cancer therapeutics.